European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics

by Marie Weil
December 22, 2021
A A
Share on LinkedinShare on Twitter

 Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics

  • Adds promising pipeline of T-cell engagers and cytokine therapies with lead candidate AMX-818 expected to enter the clinic in early 2022
  • Provides access to Amunix Pro-XTENTM, XPAT®, and XPACTM technology, complementary to Sanofi’s existing R&D platforms

PARIS – December 21, 2021 – Sanofi announced today that it has entered into an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated XTEN® and innovative universal protease-releasable masking technology platform, Pro-XTENTM, to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer. Amunix’s pipeline, which includes lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therapies in immuno-oncology. Under the terms of the agreement, Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones. The acquisition supports Sanofi’s efforts to accelerate and expand its contributions to innovative medicines for oncology patients, with approximately 20 molecules currently in development. 

“This acquisition demonstrates our ongoing commitment to investing in promising research and discovery platforms,” said John Reed, M.D., Ph.D., Global Head of Research & Development, Sanofi. “The Amunix technology platform utilizes a next generation smart biologics approach to precisely tailor–deliver medicines to become active only in tumor tissues while sparing normal tissues, thus bringing the promise of more effective and safer treatment options for cancer patients. We are excited to rapidly advance Amunix’s promising pipeline and to combine their innovative candidate medicines with complementary molecules in Sanofi’s immuno-oncology portfolio.”
 
Amunix’s proprietary XTEN® masks and cleavable linkers are a next-generation protein engineering approach that allows biologics to circulate in “stealth” mode, becoming active preferentially in disease specific micro-environments, with the aim to enable safer?and?more efficacious?medicines. The technology can be applied to a wide range of existing and potentially new pipeline assets. The molecular design of Amunix’s molecules endows the inactive stealth molecules with long-lasting properties, converting after activation in disease tissues to short half-life agents so that the active molecule is rapidly cleared from the body. Specifically, in immuno-oncology, Amunix’s technology offers the potential to overcome challenges that have plagued the adoption of T-Cell Engager
bi-specific antibodies for solid tumors, including unwanted immune attack of normal healthy cells and systematic widespread immune system activation that leads to side effects such as Cytokine Release Syndrome. 

“We are very proud of what the extraordinary and diverse Amunix team has accomplished in the development of our Pro-XTEN technology and rapid expansion of our pipeline,” said Angie You, Ph.D., CEO, Amunix. 

“We now look forward to combining forces with Sanofi’s team to leverage its expertise and together serve as a center of excellence in bringing these potentially better and safer drug candidates to patients,” said Volker Schellenberger, Ph.D., Co-Founder, President and Chief Technology Officer, Amunix.
         
The closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. Sanofi expects to complete the acquisition in Q1 of 2022.

Weil, Gotshal & Manges LLP is acting as Sanofi’s legal counsel. Centerview Partners LLC is acting as financial advisor to Amunix and Fenwick & West LLP is acting as its legal counsel.

XTEN, XPAT, XPAC and PRO-XTEN are trademarks in the name of Amunix.

Tags: < Invest

Related Industries

Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

January 25, 2023
Health


Philips and Masimo expand partnership to improve telehealth for patients and clinicians around the world

January 19, 2023
Health

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 10, 2023
Health

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

January 10, 2023
Health

Boehringer Ingelheim announces appointments to Board of Managing Directors

December 21, 2022
Health

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

December 20, 2022

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 10, 2023

...

TotalEnergies EP Canada acquires an additional interest in Fort Hills, ahead of its planned spin-off

January 28, 2023

...

IHG Hotels & Resorts opens global headquarters in Windsor

January 12, 2023

...

Interview with Jaime Argüelles, CEO of Duro Felguera

January 25, 2023

...

Das neue ZF-Vorstandsteam (von links nach rechts): Michael Frick, Dr. Martin Fischer, Vorstandsvorsitzender Dr. Holger Klein, Dr. Peter Laier, Sabine Jaskula und Stephan von Schuckmann.
//
ZF’s newly formed Board of Management team (from left to right): Michael Frick, Dr. Martin Fischer, CEO Dr. Holger Klein, Dr. Peter Laier, Sabine Jaskula and Stephan von Schuckmann.

ZF Kicks Off 2023 With New Executive Management Team

January 13, 2023

...

Stewart Odurny appointed Executive Vice-President Customers and Strategy of Safran Landing Systems

January 3, 2023

...

Siemens & Deloitte demonstrate Industry 4.0 innovation at The Smart Factory @ Wichita

January 20, 2023

...

Volvo EX90 to support Google’s new HD map

January 6, 2023

...

ZEISS to acquire LENSO Sp. z o.o. to strengthen market access and industry expertise in 3D metrology and inspection solutions in Poland

January 13, 2023

...

HOLCIM ACQUIRES NICEM

January 11, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist